Sign Out
Use in Pregnancy: A post-marketing acyclovir pregnancy registry has documented pregnancy outcomes in women exposed to any formulation of acyclovir. The registry findings have not shown an increase in the number of birth defects amongst Zovirax exposed subjects compared with the general population, and any birth defects showed no uniqueness or consistent pattern to suggest a common cause. The use of acyclovir should be considered only when the potential benefits outweigh the possibility of unknown risks.
Use in Lactation: Following oral administration of acyclovir 200 mg 5 times a day, acyclovir has been detected in breast milk at concentrations ranging from 0.6-4.1 times the corresponding plasma levels. These levels would potentially expose nursing infants to acyclovir dosages of up to 0.3 mg/kg/day. Caution is therefore advised if acyclovir is to be administered to a nursing woman.
